Clinical Trial Update: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) [Phase 3]

View source ↗

Summary

A Phase 3 study to evaluate SYH2053 Injection in patients with heterozygous familial hypercholesterolemia. The trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• SYH2053 Injection (SYH2053)

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Heterozygous Familial Hypercholesterolemia (HeFH) | Phase 3 | Status: NOT_YET_RECRUITING